Redefining CAR-T Timing and Patient Access with Allogene Therapeutics' Dr. Zachary Roberts
From Cell & Gene: The Podcast · · 18 min
This plays from the publisher's own server. We do not host a copy.
Description
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1810482/fan_mail/new)
In episode 129 of Cell & Gene: The Podcast, Host Erin Harris reconnects with Zachary Roberts, M.D., Ph.D., EVP of Research & Development and Chief Medical Officer at Allogene Therapeutics, to explore how allogeneic CAR-T is evolving from a scalability promise into an earlier-line, potentially curative intervention. Their conversation centers on the ALPHA3 trial, where MRD-guided treatment is redefining when and how CAR-T can be deployed, alongside broader implications for diagnostics, patient access, and the shift toward off-the-shelf therapies in community settings.
Subscribe to the podcast! Apple (https://podcasts.apple.com/us/podcast/cell-gene-the-podcast/id1574496063) | Spotify (https://open.spotify.com/show/78NSjRuHndVhI5VHWWAMya) | YouTube (https://music.youtube.com/playlist?list=PLFXsCNKV78rWyuxay7hXQFo0rVyAXAdwX)
Visit my website: Cell & Gene (https://www.cellandgene.com/)
Connect with me on LinkedIn (https://www.linkedin.com/in/erinharris/)